Methods for treating metastasis with cathepsin C inhibitors
AssigneeShanghai Institute of Nutrition and Health, Chinese Academy of Sciences
InventorsGuohong Hu, Yansen Xiao, Min Cong, Chenxi Liang
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treating metastasis of a cancer with a pharmaceutical composition comprising an effective amount of a cathepsin C (CTSC) inhibitor. The CTSC inhibitor, in some embodiments, is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for example, brensocatib. The treatment methods inhibit, slow, or reverse the progression of the metastasis. In some embodiments, the methods further comprise reducing neutrophil infiltration and/or formation of neutrophil extracellular traps (NETs).
Claims12
A method of treating a metastasis of a cancer in a patient in need thereof, comprising, administering to the patient in need of treatment for a treatment period, a pharmaceutical composition comprising an effective amount of a cathepsin C (CTSC) inhibitor, wherein the administering inhibits, slows, or reverses the progression of the metastasis, and the administering reduces the formation of neutrophil extracellular traps (NETs), reduces neutrophil migration, or both at the site of metastasis during the treatment period or subsequent to the treatment period;
- wherein the patient in need thereof has elevated serological levels of CTSC protein prior to the administering, and wherein the administering reduces the serological levels of CTSC protein in the patient in need thereof by about 25% to about 75%;
- wherein the CTSC inhibitor is brensocatib:
- or a pharmaceutically acceptable salt thereof.
A method of treating a primary cancer in a patient in need thereof, comprising, administering to the patient in need of treatment for a treatment period, a pharmaceutical composition comprising an effective amount of a cathepsin C (CTSC) inhibitor, wherein the administering inhibits, slows, or reverses the progression of the primary cancer, and the administering reduces the formation of neutrophil extracellular traps (NETs), reduces neutrophil migration, or both in the primary cancer during the treatment period or subsequent to the treatment period;
- wherein the patient in need thereof has elevated serological levels of CTSC protein prior to the administering, and wherein the administering reduces the serological levels of CTSC protein in the patient in need thereof by about 25% to about 75%;
- wherein the CTSC inhibitor is brensocatib:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.